Intravenous Iron Infusion

Early iron preparations and iron dextran

A 2014 review by Auerbach and Macdougall describes early parenteral iron as causing severe acute reactions and being considered unsuitable for general use. Iron dextran arrived in 1954 and was easier to give, though serious reactions still occurred infrequently. The review cites a 1980 prospective study of 471 patients that recorded three cases of anaphylaxis, after which its authors limited intravenous iron to situations where oral iron was not an option.

The same review links renewed demand in the late 1980s to erythropoiesis-stimulating agents in dialysis patients. A high-molecular-weight iron dextran product was the main option until it was recalled in 1991 after a contaminated lot, and a low-molecular-weight product replaced it. A second high-molecular-weight product was approved in 1996, and the review reports that a 1998 analysis attributed virtually all serious iron dextran reactions to it.

Newer non-dextran products

Auerbach and Macdougall state that ferric gluconate and iron sucrose were approved in the United States in 1999 and 2000, and that ferumoxytol, ferric carboxymaltose and iron isomaltoside (marketed in Europe) later allowed larger amounts of iron to be given in a single session. A 2023 review lists the non-dextran products now in use as iron sucrose, ferric carboxymaltose, ferric derisomaltose and ferumoxytol.

Auerbach and Macdougall conclude that, once high-molecular-weight iron dextran is avoided, the remaining formulations are probably much safer than most physicians realize. One author disclosed consultancy, lecture or research funding from several intravenous iron manufacturers, and the claim is a review-level judgment rather than a trial result.

Names and product groups

Sources use intravenous iron, parenteral iron and iron infusion interchangeably. The British Society of Gastroenterology guideline uses the phrase parenteral iron replacement therapy, with oral iron replacement therapy as the comparator. Named products in the reviews and guidelines cited here include iron sucrose, ferric carboxymaltose, ferric derisomaltose (also called iron isomaltoside), ferumoxytol and iron dextran-type products. Brand names and availability differ between countries and are not covered here.

Relation to other Machipedia pages

This page is a member of the Machipedia family page named IV Therapy and does not repeat that page's overview of infusion-based practices. It describes one standard medical treatment so that readers can compare it with elective wellness infusions covered elsewhere. Related Machipedia pages include IV Therapy, Intravenous Fluid Therapy, Nutritional Therapy, Dietetics and Herbal Medicine. The sources used here do not define a separate term for elective iron infusions given without a diagnosis.

Diagnosis comes first

The British Society of Gastroenterology guideline states that iron-deficiency anemia can generally be diagnosed by blood testing and treated with iron replacement by the oral or intravenous route. It adds that about a third of men and postmenopausal women presenting with the condition have an underlying pathological abnormality, most commonly in the gastrointestinal tract, so management combines iron replacement with investigation of the cause.

NICE guidance on chronic kidney disease advises testing every three months to diagnose iron deficiency and judge responsiveness to iron therapy, with more frequent checks for people having hemodialysis. It also advises against using transferrin saturation or serum ferritin alone to assess iron status in anemia of chronic kidney disease.

Setting and supervision

The British Society of Gastroenterology guideline recommends that service providers aim to have an ambulatory care base for giving parenteral iron. NICE states that intravenous iron should be given in a setting with facilities for resuscitation. A 2013 European Medicines Agency review concluded that these medicines should be given only where staff trained to manage anaphylactic reactions and resuscitation facilities are immediately available, with observation during and for at least 30 minutes after each injection.

Where guidelines place intravenous iron

The British Society of Gastroenterology guideline recommends that parenteral iron be considered when oral iron is contraindicated, ineffective or not tolerated, and earlier when oral treatment is judged unlikely to work or correction is particularly urgent. It describes the intravenous route as possibly preferable from the outset with ongoing significant bleeding, gastrointestinal malabsorption, combined iron deficiency and inflammation, or problems with administration or adherence. It notes that oral iron is generally preferred on cost and convenience because efficacy is comparable for most patients.

For inflammatory bowel disease, the same guideline says parenteral iron may be required when oral iron is not tolerated or absorbed. For chronic heart failure with functional iron deficiency, it states that parenteral iron may improve symptoms and quality of life, and it refers readers to specialist guidelines for kidney and heart conditions.

Kidney disease and pregnancy

NICE guidance on chronic kidney disease advises that people who are not having hemodialysis should be considered for a trial of oral iron first, with intravenous iron offered if oral iron is not tolerated or target hemoglobin is not reached within three months. It also advises offering an intravenous iron regimen to people with stage 5 disease on in-centre hemodialysis who have iron deficiency.

For pregnancy, a 2026 audit of 49 National Health Service sites reports that British Society of Haematology guidance states there is insufficient evidence to support iron hydroxide dextran in pregnancy, and that 82 percent of local guidelines recommended ferric carboxymaltose or ferric derisomaltose. The authors concluded intravenous iron was generally not first-line locally, and thresholds for starting it ranged widely between sites. The European Medicines Agency review limits use in pregnancy to the second or third trimester and only where benefit clearly outweighs risk to the fetus.

Pregnancy

A 2026 systematic review and meta-analysis in JAMA Network Open pooled 29 randomized trials with 11,771 participants comparing intravenous and oral iron for iron-deficiency anemia in pregnancy. Intravenous iron was associated with higher maternal hemoglobin at delivery (mean difference 0.59 g/dL across 15 studies), higher ferritin, and fewer blood transfusions (relative risk 0.63). No serious adverse events were reported, and mild adverse effects were less frequent with intravenous iron.

The authors note high heterogeneity, signs of possible publication bias, lower quality ratings for 13 of the 29 trials, and sparse reporting of neonatal outcomes. They describe their findings as supporting a possible greater role for intravenous iron rather than as settling the question.

Heart failure

A 2026 umbrella review of systematic reviews found that intravenous iron, mostly ferric carboxymaltose, reduced the composite of heart failure hospitalization and cardiovascular death in people with heart failure with reduced ejection fraction, chiefly through fewer hospitalizations. A survival benefit was not established. The authors caution that the reviews share many of the same older trials, that evidence for other products is limited, and that findings should not be extended to heart failure with preserved ejection fraction.

Comparisons between products

A 2026 network meta-analysis of 55 randomized trials with 23,302 participants compared six intravenous iron formulations with oral iron and each other. Over the first weeks, ferric carboxymaltose raised ferritin and transferrin saturation more consistently, at the cost of a higher risk of low phosphate. Hemoglobin effects were broadly comparable between ferric carboxymaltose and ferric derisomaltose. The authors list heterogeneous regimens, sparse timepoints and inconsistent hypophosphatemia thresholds as limits.

The reviews summarized here are not Cochrane reviews. A search for a Cochrane review comparing intravenous and oral iron in heart failure, kidney disease, pregnancy or the postpartum period did not identify one that could be cited with confidence for this page.

Infusion and hypersensitivity reactions

A 2023 review describes a transient flushing reaction (often called a Fishbane reaction), a complement-related pseudo-allergic reaction, and true anaphylaxis, which it calls extremely rare but potentially life-threatening. For non-dextran products it cites severe hypersensitivity in about 0.024 percent of infusions and anaphylaxis in about 0.018 percent.

The British Society of Gastroenterology guideline states that infusion-related reactions are uncommon with modern preparations, that hypersensitivity-type reactions are more common than with oral iron or placebo, and that serious reaction rates are low and similar for oral and parenteral iron. The European Medicines Agency review states that all intravenous iron preparations can cause serious, sometimes fatal, hypersensitivity and that a test dose is no longer recommended.

Low phosphate with some products

The British Society of Gastroenterology guideline states that hypophosphatemia has been reported with all parenteral iron preparations, that most episodes are moderate, asymptomatic and resolve without intervention, and that the UK medicines regulator advised monitoring serum phosphate in people with risk factors and those receiving long-term or repeated ferric carboxymaltose.

A 2024 review describes a renal phosphate-wasting syndrome mediated by fibroblast growth factor 23, particularly but not uniquely linked to ferric carboxymaltose, with possible metabolic bone disease if unrecognized, and underreporting. A 2025 single-center trial of 300 postpartum women found similar low hypophosphatemia rates at six weeks with ferric carboxymaltose, ferric derisomaltose and oral iron.

Who should not receive it

The European Medicines Agency review lists as contraindications hypersensitivity to the active substance or excipients and serious hypersensitivity to other parenteral iron products, and names higher risk with known allergies, immune or inflammatory conditions, or severe asthma, eczema or atopic allergy. The British Society of Gastroenterology guideline says intravenous iron should be withheld with ongoing bacteremia.

A 2023 review notes that later studies questioned the blanket contraindication after any prior reaction, and found in five re-exposure studies totaling 1,006 people that more than 80 percent of rechallenges were tolerated, with no rechallenge after severe reactions to the same product. These decisions belong to treating clinicians.

Monitoring and contrast with elective drips

The British Society of Gastroenterology guideline advises checking the hemoglobin response after two to four weeks and periodic blood counts afterward, and says data are insufficient to recommend routine ferritin monitoring. A 2026 audit found national guidance gave no recommendations on monitoring response to intravenous iron.

No source reviewed evaluates elective wellness infusions of iron given without a diagnosis. Each guideline cited ties intravenous iron to diagnosed deficiency, blood testing and a setting able to manage reactions. This page is not a substitute for medical care.